Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma. - Test2 - elhamkhani - TriplyDB

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

http://www.wikidata.org/entity/Q33359342

about

Optic nerve head and fibre layer imaging for diagnosing glaucoma Optic nerve head and fibre layer imaging for diagnosing glaucoma 24-h Efficacy of Glaucoma Treatment Options Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data Prospective, non-interventional, multicenter study of the intraocular pressure-lowering effects of prostaglandin analog/prostamide-containing therapies in previously treated patients with open-angle glaucoma or ocular hypertension.Real-time imaging of single neuronal cell apoptosis in patients with glaucoma.Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial.Selected autoantibodies and normal-tension glaucoma.Portsmouth visual field database: an audit of glaucoma progression Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.Prevalence and associated factors of glaucoma in rural central India. The Central India Eye and Medical Study.Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial.Relationship between progression of visual field defect and intraocular pressure in primary open-angle glaucoma Glaucoma Structural and Functional Progression in American and Korean Cohorts.Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension.Risk Factors for Primary Open Angle Glaucoma (POAG) Progression: A Study Ruled in Torino Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucoma Bimatoprost/timolol fixed combination (BTFC) in patients with primary open angle glaucoma or ocular hypertension in Greece.Evaluation of the associations between changes in intraocular pressure and metabolic syndrome parameters: a retrospective cohort study in Japan.A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.Morphology of optic disc through heidelberg retina tomograph in retinal vein occlusions alone or in combination with primary open angle glaucoma.Maladaptive coping strategies and glaucoma progression.Rates of visual field progression in clinical glaucoma care IOP elevation reduces Schlemm's canal cross-sectional area.Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients The influence of the assessment method on the incidence of visual field progression in glaucoma: a network meta-analysis.Focusing on glaucoma progression and the clinical importance of progression rate measurement: a review.Role of fixed combinations in the management of open-angle glaucoma.Perimetry, tonometry and epidemiology: the fate of glaucoma management.Demonstration of an online tool to assist managed care formulary evidence-based decision making: meta-analysis of topical prostaglandin analog efficacy.Relationship between consecutive deterioration of mean deviation value and progression of visual field defect in open-angle glaucoma.Evaluation of the new digital goldmann applanation tonometer for measuring intraocular pressure.Impact of a Brief Educational Intervention on Glaucoma Persistence: A Randomized Controlled Clinical Trial.Progression of visual field in patients with primary open-angle glaucoma - ProgF study 1.

P2860

Q24187597-4AD7B200-1337-43BF-8BCE-E86B89F27BD5 Q24236729-429AAD37-1BB1-4F86-99F5-880AA5BF8444 Q26766594-698D8032-B518-48C1-A1CD-F68C39BF864B Q30990445-A96AAB90-BC63-4B0A-AF1A-69571A5C67CF Q33596855-D15C12B6-F954-44A5-9449-4E1AEC3E295F Q33729892-2A38976B-F7F2-4B77-A068-B27D719D4DDD Q33834484-B97883C0-47CF-406B-BA22-266DD8C2A08D Q33933715-39309AAA-E984-4180-9FEE-B93FCF7C488F Q34055002-4F03F26A-DAED-4A65-A825-CC84D2E47E2D Q34188272-629D6A16-174B-41D3-A339-5370EEC22FE4 Q34253481-38AD80B6-FE21-4562-83F0-DA411FF34355 Q34981291-B53BABE8-44ED-4667-9A8A-D4880A482F25 Q35010319-FA4AF45D-904B-4AA7-80C0-B281DACFC16E Q35015841-728A8445-8A53-49DB-A5CA-8F26FE1A2014 Q35102806-8094D0C1-F7B4-48BD-9B81-EBF7B02C1F95 Q35681331-3F31F83F-357C-4FBA-B551-C48B80F7EEF1 Q35814361-9DF9A2A9-42F4-4B8F-90BE-FD183C167BC9 Q35822206-6F10FFE4-870A-4210-8CB9-50E40B3383A4 Q35892410-45A2061D-83B1-4E5A-8C22-EF7166C142EF Q35896575-B5A66A23-6521-4FF5-BCFB-8B1D7A848328 Q35997507-F7E0023B-AC88-4288-8415-61771E43504E Q36062102-E0243C76-CC8D-4B35-A8AB-87571501D337 Q36173758-F68F7DF8-393F-41C7-907D-A5713439D885 Q36622405-8F300860-92A4-41F0-8925-DC1FB724FDA4 Q36732907-91EEA656-98A1-4B64-B93B-C8A7B0A90985 Q36958046-DAA7C25C-DCBE-48C1-B24B-5C7FBA5E30DE Q37098557-1D0A83B1-BAD1-4737-B2F1-B4A0EDB7127D Q37226454-3B28B4F1-4F96-4F1B-A89D-B4060D3CF147 Q37233278-C92A1ED8-6A23-407A-BF52-861F433310A4 Q37671072-3CF0FF35-02DD-484E-91DF-EAE6972D75C3 Q37697869-3FA6C163-AA15-4A0C-9C1E-95270795C0B4 Q37799863-86583E35-D1F7-4BD2-94B1-1174A680B8F6 Q37800022-31C6EC34-D781-43F8-A795-698FB9F06DBE Q37847155-381D9761-E5B1-4567-88DF-0825306434C2 Q37880251-E1B96ECC-A1DC-4439-B467-90FF5D068909 Q37918357-7D8D508B-45C4-4888-B2BE-BD59B0D31DFD Q38934037-BA02AFA5-62E9-4A2C-AEB6-DBE9BB376891 Q40215149-13065711-C397-4438-AC3C-FCB5F63C5761 Q40226467-1A68B19A-0B38-40FE-9674-B98624C8587A Q40814918-70BB9E2B-E2A0-4863-93F2-F70AA6367847

P2860

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

http://www.wikidata.org/entity/Q33359342

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@ast

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@en

type

label

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@ast

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@en

prefLabel

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@ast

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@en

P1433

Q33359342-BDFF7FE3-908F-4E40-9D0E-595760D9E543

P1476

Q33359342-74B97DA4-7DDD-427F-9360-1255121E6247

P2093

Q33359342-18681135-F257-4EE2-A2C1-071D76B9783D

Q33359342-3196EC0C-072E-4C76-BA73-67AC61BFAA66

Q33359342-416666FC-453D-4A26-BC6A-DECBA4134A25

Q33359342-44E82D7F-9579-41BF-B0C7-73E334B73F57

Q33359342-600D94CC-535F-4193-ADDA-CC7A10843FA0

Q33359342-7729DFC6-36F5-41DE-8698-7E849C8560E6

Q33359342-CF810BEC-B9A6-4332-9426-DF2B24A38E7E

P304

Q33359342-F29FA72B-EF8E-4CE8-AEA3-54ECF52E1B7B

P31

Q33359342-6E45DC89-BB43-4208-BF61-51D961092FBF

P356

Q33359342-DB545712-E174-4514-BAC8-4CD0A7392DED

P407

Q33359342-BAA08AB8-A62C-4ACF-AD4C-10FE2821059F

P433

Q33359342-DEC977C3-E1A3-4106-A402-3779BD486EF1

P478

Q33359342-AD3E9FFB-6771-4F99-A98A-6A92992DE1EC

P577

Q33359342-1766664B-1CDA-4378-AAFE-F33D36BCFC9E

P5875

Q33359342-3D02FFD1-CCE5-44B1-9059-89EBA9BC62D6

P698

Q33359342-65C690A2-16C1-4777-A2C9-B92C73B1DD2A

P356

ARCHOPHT.126.8.1030

P1433

JAMA Ophthalmology

P1476

Canadian Glaucoma Study: 2. risk factors for the progression of open-angle glaucoma.

@en

P2093

A Gordon Balaszi

http://www.w3.org/2001/XMLSchema#string

Balwantray C Chauhan

http://www.w3.org/2001/XMLSchema#string

Canadian Glaucoma Study Group

http://www.w3.org/2001/XMLSchema#string

Frederick S Mikelberg

http://www.w3.org/2001/XMLSchema#string

Graham E Trope

http://www.w3.org/2001/XMLSchema#string

Mark R Lesk

http://www.w3.org/2001/XMLSchema#string

Raymond P LeBlanc

http://www.w3.org/2001/XMLSchema#string

P304

1030-1036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHOPHT.126.8.1030

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

126

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23163723

http://www.w3.org/2001/XMLSchema#string

P698

18695095

http://www.w3.org/2001/XMLSchema#string